Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about the company's own repeatable business escalating in unit size. The transcript discusses various initiatives: store openings, Curve stores, Studio launch, etc. But does management say that each new instance of a program is larger than before? For example, store openings: they plan to open 34 stores for the year, including 8 Curve stores. But that's just a count, not necessarily larger per store. They mention doubling distribution center capacity, but that's infrastructure, not engagements. They talk about marketing and promotions, but not about deal size. They mention new ERP system, but that's internal. They talk about private label credit card agreement, but not about size escalation. They mention "biggest launch in our brands history" for Studio, but that's a product launch, not a repeatable engagement. The question is about successive engagements of the same kind coming in at progressively larger size. For example, if they said "our new stores are larger than previous stores" or "our Curve stores are bigger" or "our contracts are bigger". Nothing like that. They talk about opening stores, but not about size of each store. They talk about Curve test stores, but not about them being larger. They talk about marketing spend efficiency, but not about larger deals. They talk about inventory levels, but that's not engagements. So no evidence of escalation in unit size. They also mention "we have plans to innovate our assortment" but that's not about size. The answer is NO. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.